Cargando…

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values

OBJECTIVE: The aim of the study was to analyze John Cunningham virus (JCV) serology in natalizumab-treated patients over time and assess whether they are influenced by natalizumab treatment. METHODS: German (n = 1,921; 525 longitudinally) and French (n = 1,259; 711 longitudinally) patients were asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwab, Nicholas, Schneider-Hohendorf, Tilman, Pignolet, Béatrice, Breuer, Johanna, Gross, Catharina C., Göbel, Kerstin, Brassat, David, Wiendl, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733149/
https://www.ncbi.nlm.nih.gov/pubmed/26848486
http://dx.doi.org/10.1212/NXI.0000000000000195
_version_ 1782412801543766016
author Schwab, Nicholas
Schneider-Hohendorf, Tilman
Pignolet, Béatrice
Breuer, Johanna
Gross, Catharina C.
Göbel, Kerstin
Brassat, David
Wiendl, Heinz
author_facet Schwab, Nicholas
Schneider-Hohendorf, Tilman
Pignolet, Béatrice
Breuer, Johanna
Gross, Catharina C.
Göbel, Kerstin
Brassat, David
Wiendl, Heinz
author_sort Schwab, Nicholas
collection PubMed
description OBJECTIVE: The aim of the study was to analyze John Cunningham virus (JCV) serology in natalizumab-treated patients over time and assess whether they are influenced by natalizumab treatment. METHODS: German (n = 1,921; 525 longitudinally) and French (n = 1,259; 711 longitudinally) patients were assessed for JCV serology alongside their therapy with natalizumab. RESULTS: JCV serostatus changed in 69 of 525 longitudinally followed German patients (13.1%) over 14.8 months. Seroconversion according to serostatus was seen in 43 of 339 initially JCV− German patients (12.7% in 14.8 months; 10.3% per year) and 41 of 243 initially JCV− French patients (16.9% in 24 months; 8.5% per year). JCV index values could be reproduced (R(2) = 0.89) with the caveat of 8 of 50 samples (16%) being set into different risk categories between 2 assessments. Index values of JCV+ patients rose over time (p = 0.009) but not because of aging. Treatment with natalizumab was associated with a 15.9% increase of value in JCV+ patients in 14.8 months (12.9% per year). CONCLUSIONS: JCV seroconversion and index values may be influenced by treatment with natalizumab. It is therefore important to monitor patients' JCV serology but also to incorporate additional risk factors into the progressive multifocal leukoencephalopathy risk stratification.
format Online
Article
Text
id pubmed-4733149
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-47331492016-02-04 Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values Schwab, Nicholas Schneider-Hohendorf, Tilman Pignolet, Béatrice Breuer, Johanna Gross, Catharina C. Göbel, Kerstin Brassat, David Wiendl, Heinz Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: The aim of the study was to analyze John Cunningham virus (JCV) serology in natalizumab-treated patients over time and assess whether they are influenced by natalizumab treatment. METHODS: German (n = 1,921; 525 longitudinally) and French (n = 1,259; 711 longitudinally) patients were assessed for JCV serology alongside their therapy with natalizumab. RESULTS: JCV serostatus changed in 69 of 525 longitudinally followed German patients (13.1%) over 14.8 months. Seroconversion according to serostatus was seen in 43 of 339 initially JCV− German patients (12.7% in 14.8 months; 10.3% per year) and 41 of 243 initially JCV− French patients (16.9% in 24 months; 8.5% per year). JCV index values could be reproduced (R(2) = 0.89) with the caveat of 8 of 50 samples (16%) being set into different risk categories between 2 assessments. Index values of JCV+ patients rose over time (p = 0.009) but not because of aging. Treatment with natalizumab was associated with a 15.9% increase of value in JCV+ patients in 14.8 months (12.9% per year). CONCLUSIONS: JCV seroconversion and index values may be influenced by treatment with natalizumab. It is therefore important to monitor patients' JCV serology but also to incorporate additional risk factors into the progressive multifocal leukoencephalopathy risk stratification. Lippincott Williams & Wilkins 2016-01-27 /pmc/articles/PMC4733149/ /pubmed/26848486 http://dx.doi.org/10.1212/NXI.0000000000000195 Text en © 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Article
Schwab, Nicholas
Schneider-Hohendorf, Tilman
Pignolet, Béatrice
Breuer, Johanna
Gross, Catharina C.
Göbel, Kerstin
Brassat, David
Wiendl, Heinz
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
title Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
title_full Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
title_fullStr Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
title_full_unstemmed Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
title_short Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
title_sort therapy with natalizumab is associated with high jcv seroconversion and rising jcv index values
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733149/
https://www.ncbi.nlm.nih.gov/pubmed/26848486
http://dx.doi.org/10.1212/NXI.0000000000000195
work_keys_str_mv AT schwabnicholas therapywithnatalizumabisassociatedwithhighjcvseroconversionandrisingjcvindexvalues
AT schneiderhohendorftilman therapywithnatalizumabisassociatedwithhighjcvseroconversionandrisingjcvindexvalues
AT pignoletbeatrice therapywithnatalizumabisassociatedwithhighjcvseroconversionandrisingjcvindexvalues
AT breuerjohanna therapywithnatalizumabisassociatedwithhighjcvseroconversionandrisingjcvindexvalues
AT grosscatharinac therapywithnatalizumabisassociatedwithhighjcvseroconversionandrisingjcvindexvalues
AT gobelkerstin therapywithnatalizumabisassociatedwithhighjcvseroconversionandrisingjcvindexvalues
AT brassatdavid therapywithnatalizumabisassociatedwithhighjcvseroconversionandrisingjcvindexvalues
AT wiendlheinz therapywithnatalizumabisassociatedwithhighjcvseroconversionandrisingjcvindexvalues